Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in Acute Ischemic Stroke
NCT03287076Phase 2Unknown
- Sponsor
- Neuroscience Trials Australia
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of exenatide in ischemic stroke, sponsored by Neuroscience Trials Australia. Primary endpoint: Improved neurological outcome at 7 days. Status: unknown.
02
Drugs
exenatide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03287076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287076.